HCW Biologics/$HCWB
1D1W1MYTD1Y5YMAX
About HCW Biologics
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
- Ticker
- $HCWB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 35
- Headquarters
- Miramar, United States
- Website
- www.hcwbiologics.com
HCW Biologics Metrics
BasicAdvanced
$5.8M
-
-$27.18
2.36
-
Price and volume
Market cap
$5.8M
Beta
2.36
52-week high
$38.16
52-week low
$1.50
Average daily volume
136K
Financial strength
Current ratio
0.061
Quick ratio
0.041
Total debt to equity
88.337
Interest coverage (TTM)
-11.26%
Profitability
EBITDA (TTM)
-5.585
Gross margin (TTM)
95.91%
Net profit margin (TTM)
-83.05%
Operating margin (TTM)
-92.01%
Effective tax rate (TTM)
-6.29%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-13.88%
Return on equity (TTM)
-151.36%
Valuation
Price to revenue (TTM)
0.371
Price to book
0.69
Price to tangible book (TTM)
0.69
Price to free cash flow (TTM)
-0.206
Free cash flow yield (TTM)
-486.14%
Free cash flow per share (TTM)
-15.41
Growth
Revenue change (TTM)
707.02%
Earnings per share change (TTM)
-74.25%
3-year revenue growth (CAGR)
20.77%
3-year earnings per share growth (CAGR)
-39.89%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.